AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02234882 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Study NCT02234882 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-663068
Study NCT02946580 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MOVANTIK™ (naloxegol)
Study NCT02946580 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sugar Pill
Study NCT04003701 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: Control group: minimal distraction
Study NCT04003701 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Robot-assisted puncture procedure
Description: Experimental group: distraction with robot
Study NCT01729780 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: EEG-NF
Study NCT01729780 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: EEG-NF
Study NCT01933737 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Kinesio Taping
Description: The Kinesio Taping group (KTG) (n = 31 elderly women) were submitted to the protocol of applying Kinesio Taping for gastrocnemius muscle and the muscles of the median foot. The application of the tapes was bilateral limbs. The subjects were evaluated post-application and 48 hours after application of the tape.
Study NCT01933737 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 3M Micropore
Description: The placebo tape group (PTG) (n = 31 elderly women) were submitted to the protocol of applying placebo tape (3M Micropore) for gastrocnemius muscle and the muscles of the median foot in the same way that KTG. The application of the tapes was bilateral limbs. The subjects were evaluated post-application and 48 hours after application of the tape.
Study NCT01915784 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Genuair®
Description: Inhaler with placebo only. Once daily, for 14 days.
Study NCT01915784 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Breezhaler®
Description: Inhaler with placebo only. Once daily, for 14 days.
Study NCT02529631 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: orlistat 60 mg
Description: In order to have comparable calorie intakes, all participants followed the recommendations of the German clinical practice guidelines on the management and prevention of obesity.~Due to the different appearance of tablets and capsules, a double dummy design was chosen, a blister strip for each day and each participant had to take the same amount of capsules and tablets per day. The content of the blister strips: three orlistat 60 g capsules plus six placebo tablets.
Study NCT02529631 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: polyglucosamine
Description: In order to have comparable calorie intakes, all participants followed the recommendations of the German clinical practice guidelines on the management and prevention of obesity.~Due to the different appearance of tablets and capsules, a double dummy design was chosen, a blister strip for each day and each participant had to take the same amount of capsules and tablets per day. The content of the blister strips: three blue placebo capsules plus two placebo tablets (morning) and four polyglucosamine tablets (noon and evening).
Study NCT03095690 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: High resolution peripheral scanner (HRpQCT).
Description: radius and tibia osteodensitometry measurement
Study NCT04219579 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antithrombin III, continuous infusion
Description: Antithrombin-III is administered continuously
Study NCT04219579 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Antithrombin III, Intermittent infusion
Description: Antithrombin-III is administered intermittently
Study NCT02579499 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fixed high potent statin therapy
Description: Patients assigned fixed high-potent statin group will be received high-intensity statin therapy (atorvastatin 40mg or rosuvastatin 20mg) regardless of their baseline LDL-C levels, and maintain high-intensity statin therapy regardless of their follow-up LDL-C level.
Study NCT02579499 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: targeted LDL-C goal statin
Description: 1. Statin naïve patients: Patients will be received moderate intensity statin therapy (atorvastatin 20mg or rosuvastatin 10mg)~2. Patients already received statin therapy~   * Baseline LDL-C \<70mg: same intensity of statin therapy~  * Baseline LDL-C≥70mg: uptiltrated statin therapy Patients will be tiltrated statin intensity guided by follow-up LDL-C level ( Attained LDL-C \< 50mg/dL : down regulated intensity statin therapy, 50mg/dL ≤ Attained LDL-C \< 70g/dL: maintain current intensity statin therapy, Attained LDL-C ≥ 70mg/dL: up regulated intensity statin therapy)
Study NCT00677326 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VEGFR1 and VEGFR2
Description: Patients will be vaccinated twice a week for 8 weeks. On each vaccination day, VEGFR1 peptide (1mg) and VEGFR2 peptide (1mg) mixed with Montanide ISA 51 will be administered by subcutaneous injection.
Study NCT02749435 — intervention group
Intervention type: OTHER
Intervention: Use of digital disease management tool in participants with T2DM
Description: The purpose of this study is to evaluate if the provision of a digital disease management tool in addition to standard care for T2DM, will improve glycaemic control. The impact of the tool will be assessed in comparison to a Control group who will receive standard care alone. All participants will complete the PRO assessments. This is a real-world study carried out at the point of care intended to assist health care practitioners and managed care providers to make evidence-based decisions about how to improve participant self-management of their diabetes.
Study NCT05057299 — intervention group
Intervention type: OTHER
Intervention: retrospective data analysis
Description: chart review, analysis and reporting outcomes
Study NCT01528176 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: 10,000 IU of cholecalciferol for a total of 8 weeks
Description: Subjects were treated with weekly oral administration of 10,000 IU of cholecalciferol for a total of 8 weeks in order to correct the vitamin D deficiency.
Study NCT01184144 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pioglitazone
Description: Pioglitazone, 30 mg, by mouth daily for 2 weeks
Study NCT01617824 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linagliptin
Description: Linagliptin 5 mg tablets for 4 days
Study NCT01617824 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablets for 4 days
Study NCT01391962 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cediranib
Description: Cediranib, a small molecule inhibitor of vascular endothelial growth factor (VEGF) receptor tyrosine kinases, is showing preliminary evidence of activity in patients with alveolar soft part sarcoma (ASPS).
Study NCT01391962 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sunitinib
Description: Sunitinib, a small molecule inhibitor of vascular endothelial growth factor (VEGF) receptor tyrosine kinases, is showing preliminary evidence of activity in patients with alveolar soft part sarcoma (ASPS).
Study NCT01391962 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Prochlorperazine
Description: 10mg every 6 hours orally as needed for nausea,
Study NCT01391962 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Promethazine
Description: 12.5-25mg intravenous every 6 hours as needed for nausea.
Study NCT01391962 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Benzodiazepine
Description: If promethazine is inadequate, add benzodiazepine until acute nausea is controlled.
Study NCT01391962 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Filgrastim
Description: Therapeutic use per investigator's discretion according to American Society of Clinical Oncology (ASCO) guidelines.
Study NCT01391962 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sargramostim
Description: Therapeutic use per investigator's discretion according to American Society of Clinical Oncology (ASCO) guidelines.
Study NCT01819259 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nicotine nasal spray
Description: This study will use nicotine nasal spray to safely and effectively model the effects of initial smoking experiences in nonsmokers. Neither the safety nor the effectiveness of this drug will be assessed. The overall goal of the proposed research is to evaluate the behavioral and genetic mechanisms of smoking risk in non-smoking young adults (aged 18-25 years of age) with and without ADHD using a novel laboratory-based model of intranasal nicotine administration. The effects of two doses of intranasally administered nicotine versus placebo will be assessed. In addition, nicotine self-administration will be evaluated under conditions that are likely to be more cognitively challenging among individuals with ADHD.
Study NCT01391962 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lomotil
Description: 2.5mg plus atropine sulfate 0.025mg/tablet dosed according to package insert.
Study NCT01391962 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Loperamide
Description: 4mg by mouth (PO) after first unformed stool with 2mg PO every 2 hours as long as unformed stools continue.
Study NCT01391962 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vitamin B6
Description: 50-150mg orally each day for hand-foot syndrome.
Study NCT01391962 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aquaphor
Description: Topical emollient for hand-foot syndrome.
Study NCT01391962 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen
Description: Analgesic for hand foot syndrome as needed.
Study NCT01391962 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levothyroxine
Description: Replacement therapy for participants with increases in thyroid-stimulating hormone.
Study NCT01391962 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Warfarin
Description: 2mg daily for prophylaxis of thrombosis.
Study NCT04291781 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RC18 160mg
Description: subcutaneous injection on the upper arm, abdomen, or upper thigh outside;
Study NCT04291781 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RC18 240mg
Description: subcutaneous injection on the upper arm, abdomen, or upper thigh outside;
Study NCT04291781 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: subcutaneous injection on the upper arm, abdomen, or upper thigh outside;
Study NCT04011176 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Standard treatment + placebo
Description: Placebo microcurrent
Study NCT04011176 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Standard treatment + Microcurrent Therapy
Description: Actual microcurrent
Study NCT03536572 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sleep Apnea Self-Management Program
Description: Protocol-based sleep apnea and CPAP education and support
Study NCT03536572 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Sleep Apnea Self-Management Program
Description: Protocol-based sleep apnea and CPAP education and support
Study NCT03131024 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 50% caloric restriction
Description: Meals mimicking participant dietary preferences and matching North American macronutrient guidelines will be provided consisting of 50% of total caloric intake for 48 hours
Study NCT03131024 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic exercise
Description: The supervised exercise session will consist of a 10-minute warm-up, 30 minutes performed at 70-75% of heart rate reserve, which corresponds to a vigorous intensity, followed by a 5-minute cool-down
Study NCT03879512 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: depletion of regulatory T cells
Description: oral metronomic cyclophosphamide
Study NCT03879512 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: reoperation
Description: resection of relapsed tumor in order to improve clinical condition of the patient and to acquire tumor tissue for vaccine generation
Study NCT03879512 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: cancer vaccine
Description: 4 weekly intradermal injections of lysate-loaded dendritic cells, followed by 3 monthly boost vaccines with tumor lysate and further boost vaccines every three months
Study NCT03879512 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: checkpoint blockade
Description: Immediately one week after the DC-induction vaccines, patients will receive four applications of Nivolumab/Ipilimumab double checkpoint blockade in threeweekly intervals, followed by Nivolumab monotherapy every month for a total duration of one year.
Study NCT03815929 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Estradiol 100 Micrograms Patch
Description: Standard
Study NCT03815929 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Estradiol Patch
Description: Individualized
Study NCT04544813 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-77474462
Description: Participants will receive JNJ-77474462 as a liquid formulation in Cohort A, B, C, D, F and G (SC injection) and in Cohort E, H and I (IV infusion).
Study NCT04544813 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anakinra
Description: Participants will receive a SC injection of anakinra 100 mg once daily for 3 days.
Study NCT03571438 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: CK2 and ATM inhibitors serine/ threonin Kinase combination
Description: Treatment of cell culture with CK2 and ATM inhibitors serine/ threonin Kinase combination
Study NCT03571438 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sunitinib
Description: Treatment of cell culture with Sunitinib
Study NCT03571438 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pazopanib
Description: Treatment of cell culture with Pazopanib
Study NCT03571438 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Temsirolimus
Description: Treatment of cell culture with Temsirolimus
Study NCT02620774 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ceftolozane/tazobactam
Description: 3 or more doses of ceftolozane/tazobactam intravenously administered over 60 minutes every 8 hours
Study NCT02620774 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ceftolozane/tazobactam
Description: 3 or more doses of ceftolozane/tazobactam intravenously administered over 60 minutes every 8 hours
Study NCT02620774 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Microdialysis Catheter Insertion
Description: A 20 kila-Dalton microdialysis probe (63 MD catheter; MDialysis Inc., N. Chelmsford, MA) will be inserted into the subcutaneous tissue at the margin of the wound (patient group) or in the thigh tissue (healthy volunteers). The probe will be left in place for the final dose and all tissue sampling procedures thereafter. This probe is perfused with a physiologic solution to collect interstitial fluid samples. The probe will then be removed after completion of sample collection.
Study NCT02620774 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Microdialysis Catheter Insertion
Description: A 20 kila-Dalton microdialysis probe (63 MD catheter; MDialysis Inc., N. Chelmsford, MA) will be inserted into the subcutaneous tissue at the margin of the wound (patient group) or in the thigh tissue (healthy volunteers). The probe will be left in place for the final dose and all tissue sampling procedures thereafter. This probe is perfused with a physiologic solution to collect interstitial fluid samples. The probe will then be removed after completion of sample collection.
Study NCT06054126 — intervention group
Intervention type: OTHER
Intervention: Echocardiography
Description: Cardiac function was evaluated by echocardiography at one year follow-up.
Study NCT01564160 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Fish Oil
Description: Source of omega-3 fatty acids.
Study NCT01564160 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: PCSO-524
Description: Extract of Greenshell Mussel
Study NCT01623570 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pergoveris: 150IU r-hFSH + 75IU r-hLH
Description: Fixed formulation of two recombinant gonadotropins
Study NCT01623570 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Menopur: HMG-HP (150 IU)
Description: Human Menopausal Gonadotropin is an urinary estract from menopausal women containing 150IU of FSH and 150 IU of LH-like activity (HCG)
Study NCT03542487 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Practice Orientation
Description: Practices will be encouraged to batch order blood glucose flowsheets for all patients with diabetes with active MyChart accounts. This will allow diabetic patients at these practices to enter any self-monitored glucose measurements. The research team will contact physicians and practice managers with an explanation of the initiative and instructions for completing batch orders and viewing entries through the system. Additionally, providers will be given a template for a secure smart-text message to send to all patients receiving the flowsheets, instructing them to enter data for the study period. The secure message will also provide them with information on how to enter data, and on the benefits of tracking blood glucose.
Study NCT03542487 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard Reminder
Description: Patients receive generic biweekly reminders, addressed from Inova Medical Group, to enter glucose measurements in the electronic flowsheets
Study NCT03542487 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Gift Card Reminder
Description: Patients receive generic biweekly reminders, addressed from Inova Medical Group, to enter glucose measurements in the electronic flowsheets. In these reminders, they will also be notified that that they will be entered to win a $50 gift card for each day entering data.
Study NCT03542487 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physician Reminders
Description: Patients receive biweekly reminders, addressed from their physician, encouraging them to enter glucose measurements in the electronic flowsheets (Note that though messages will be addressed from physician, they will be sent by Inova IT)
Study NCT04516447 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZN-c3
Description: Investigational drug
Study NCT04516447 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin is an approved drug
Study NCT04516447 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegylated liposomal doxorubicin
Description: Pegylated liposomal doxorubicin (PLD) is an approved drug
Study NCT04516447 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel is an approved drug
Study NCT04516447 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine is an approved drug
Study NCT04516447 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Combined with azenosertib
Study NCT02898181 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neuromodulation
Description: Active LLTS will be performed by use of a transcutaneous electrical nerve stimulation Parasym neuromodulation system with electrodes attached to the ear. Neuromodulation will be applied continuously for 2 hours daily.
Study NCT03056794 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: This is an observational study. The investigators will collect data about exposure to responses to dietary supplements, medications, and the ketogenic diet.
Study NCT04606134 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Hybrid fractional laser
Description: two treatments given one month apart
Study NCT04606134 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hybrid fractional laser
Description: two treatments given one month apart
Study NCT01819259 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Study NCT03805620 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Combined physical-cognitive training
Description: combined physical-cognitive training
Study NCT03805620 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physical training
Description: Multi-component physical exercise
Study NCT03805620 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive training
Description: cognitive training
Study NCT01283477 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ACUPUNCTURE AT LI11
Description: ACUPUNCTURE AT LI11 FOR 30 MINUTES PRIOR TO INTRATHECAL MORPHINE \& LEFT IN PLACE FOR 30 MINUTES
Study NCT01283477 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: SHAM ACUPUNCTURE
Description: SHAM ACUPUNCTURE AT A POINT 2 CM LATERAL TO LI11 30 MINUTES PRIOR TO INTRATHECAL MORPHINE \& LEFT IN PLACE FOR 30 MINUTES
Study NCT04606134 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Alastin Regenerating Skin Nectar with TriHex Technology
Description: applied twice daily
Study NCT04606134 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Cetaphil face cream
Description: applied twice daily